---
title: "Immunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA)… — report author — DecisionGateway"
description: "statement by report author, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d4b6-f731-7ec4-848f-6e8b93480486"
meta:
  "og:description": "statement by report author, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "Immunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA)… — report author — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **Immunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.**

A statement by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *한올바이오파마의 파트너사 이뮤노반트가 진행한 IMVT-1402의 난치성 류마티스 관절염(D2T RA) 임상 2b상에서 뛰어난 효능과 안전성이 입증되며 개발 전략의 타당성을 확보했다.*

companyreportPublished 2026-11-10 [ Read source](https://t.me/companyreport/116013)

## **Discussion**

## **Related claims**

[**Following the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6fe-7e21-bace-a811a7b3596d) [**This is the first case clinically demonstrating the strategic advantage IMVT-1402 has over Batoclimab.**하나증권 제약/바이오 김선아 · statement](https://dgw.tmarket.io/claims/01a1d887-39ae-7ac2-bbb4-dc8ff1688a98) [**IMVT-1402 is designed so its binding epitope does not compete with albumin, allowing high-dose continuous administration without hypercholesterolemia concerns, whereas Batoclimab requires dose reduction after several weeks.**하나증권 제약/바이오 김선아 · statement](https://dgw.tmarket.io/claims/01a1d887-39ba-7ec3-9b03-4f53807d90d5) [**IMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6f1-7ada-9bde-36834d645c3f) [**In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6d1-7aec-8105-c4689a803513) [**IMVT-1402 value was calculated at approximately 3.7 trillion won.**하나증권 제약/바이오 김선아 · statement](https://dgw.tmarket.io/claims/01a1d887-39e4-7726-9d43-6f9da8d87867)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,000+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f731-7ec4-848f-6e8b93480486#webpage","@type":"WebPage","description":"statement by report author, recorded recently — verbatim quote and source citation.","name":"Immunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA)… — report author — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d4b6-f731-7ec4-848f-6e8b93480486","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f731-7ec4-848f-6e8b93480486#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d4b6-f731-7ec4-848f-6e8b93480486"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f731-7ec4-848f-6e8b93480486#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"Immunovant's Phase 2b trial of IMVT-1402 in…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f731-7ec4-848f-6e8b93480486#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/companyreport/116013","text":"한올바이오파마의 파트너사 이뮤노반트가 진행한 IMVT-1402의 난치성 류마티스 관절염(D2T RA) 임상 2b상에서 뛰어난 효능과 안전성이 입증되며 개발 전략의 타당성을 확보했다.","url":"/claims/01a1d4b6-f731-7ec4-848f-6e8b93480486"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.